US Stem Cell Inc (USRM)

[Carl Spackler]

It seems that at least one person has “forgotten” the third court involved in this charade: the SCOTUS.

Their Kisor v Wilkie decision makes Ungaro’s previous ruling a non-option, if remanded to her court.
She granted summary judgement based on deference to the FDA. SCOTUS changed the rules on that with Kisor v Wilkie. Precedence has been established at “thee” highest court. Ungaro would have to play extremely loosely with the laws to find authority/jurisdiction/justification to try traveling that road again. Deference is out.